AllPennyStocks.com Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line
This section contains press releases and other materials from third parties (including paid content). AllPennyStocks.com has not reviewed this content. Please see our disclaimer.

Replimune’s First Commercial Drug Arrives—With A 2027 Cash Cliff And 2030 Finish Line

Replimune’s Tudriqev was granted accelerated approval by the FDA earlier this week, following two prior complete response letters and a 10-3 advisory committee vote in late July recommending the therapy.

Other Penny Stock Movers

The Legacy Product Is Shrinking. A New One is Growing 250%
Brazilian Developer Jumps 11% as Court Lifts Injunction
Deep Utah Porphyry Intercept Triggers 57% Rally as Drilling Continues Past 550m
Most Popular
{{ index + 1 }}


Back to Top